carbohydrate moieties with proteins are weak, with typical
dissociation constants in the high-micromolar to millimolar
range.13,14 As a consequence, many lectins interact with their
targets via multiple, homologous binding sites in order to in-
crease affinity. A well-studied example is that of the influenza virus,
which binds to cell surface sialic acids via a homotrimeric lectin
group. The initial binding allows other lectin groups on the viral
surface to come into contact with more cell surface sugars,
eventually deforming the cell membrane and leading to endocy-
tosis.3
The Escherichia coli bacterium produces toxins implicated in
a number of gastrointestinal maladies including diarrhea, hemor-
rhagic colitis, and the hemolytic uremic syndrome.15 The vero-
toxins belong to a class of toxins also known as Shiga-like toxins
(SLTs) due to their structural similarity to the Shiga toxin
produced by Shigella dysenteriae type I. Shiga-like toxins consist
of a 38.4-kDa pentameric B5 subunit, which is responsible for the
recognition of cell surface oligosaccharide units, and a 32-kDa
enzyme portion, the A subunit, which damages ribosomal RNA
once internalized by the cell.16 The cell surface recognition is a
necessary step in allowing the toxin to be internalized and fulfill
its enzymatic function. In mammalian cells, the Gb3 glycolipid is
the recognition element responsible for the binding of the Shiga
toxins.17 The carbohydrate portion of the Gb3 glycolipid is the Pk
accuracy of the analytical data from SPR measurements, as well
as the ease of use of commercial instrumentation, have allowed
researchers to ascertain binding constants from analysis of kinetic
data.
Relevant to the present work, SPR imaging has been used to
study protein-carbohydrate interactions in array format.6 Interac-
tions between immobilized monosaccharides and proteins in
noncompetitive and competitive format were analyzed. In this
work, we fabricate arrays of di- and trisaccharides to study the
binding of SLT. These arrays are employed to explore the
inhibitory effect of two synthetic compounds capable of multivalent
binding to SLT. We compare the methodology developed here to
that previously used to examine SLT inhibition.
EXPERIMENTAL SECTION
HS(CH2)11(OCH2CH2)3OCH3 (EG3-OMe) was synthesized in
accordance with known procedures.26,27 The structures of the two
probe glycosides used are shown in Figure 1. The syntheses of
bis{16-[4-O-[4-O-(R-
glucopyranosyloxy]hexadecanyl}disulfide (C16Pk) and bis{16-[4-
O-(2-acetamido-2-deoxy-â- -galactopyranosyl)-â- -glucopyranosyloxy]-
D-galactopyranosyl)-â-D-galactopyranosyl]-â-D-
D
D
hexadecanyl}disulfide (C16AGM2) were published previously.28
The inhibitors studied are shown in Figure 2. The synthesis of
the daisy inhibitor was reported previously,29 and the synthesis
of the starfish-2 inhibitor (SF-2) is presented in the supplementary
information to this paper.
trisaccharide (R-D-Galp-(1-4)-â-D-Galp-(1-4)-â-D-Glcp). It has been
shown that the binding sites of the B5 subunit can be blocked
with synthetic ligands containing multiple copies of the Pk
trisaccharide unit.16 The 5-fold quasi-symmetric ligands can bind
to all five of the strong binding sites on the B5 subunit simulta-
neously, effectively inhibiting the toxin.16,18 This system is used
here to establish the utility of SPR imaging for studies of toxin
binding inhibition.
SPR has previously been applied to the elucidation of binding
constants for various carbohydrate-protein interactions,19 espe-
cially those associated with pathogens.3,20 Some noteworthy
examples that have been studied by SPR include the binding of
HIV-1 protein gp120 to potential inhibitors composed of glyco-
dendrimers and sulfated dextran,21 the binding of the toxin ricin
to various synthetic glycolipids,22,23 and the interactions of cholera
toxin with ganglioside receptors.24,25 The sensitivity and perceived
The recombinant SLT was expressed without the enzymatic
A subunit, leaving only the self-assembling B5 subunit containing
the carbohydrate recognition sites and purified according to
published procedures.30 A 1.6 mg/mL concentration of SLT in PBS
with 0.02% NaN3 as preservative was used as a stock solution.
Protein solutions were diluted in phosphate-buffered saline
(PBS: 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, 2.7
mM KCl in 18 MΩ water).
Poly(dimethylsiloxane) (PDMS) microfluidic channels were
fabricated according to established methods.31 Briefly, a relief
pattern of photoresist on a silicon wafer was created photolitho-
graphically. By curing PDMS prepolymer and cross-linker (Syl-
gard 184, Dow Corning; Midland, MI) 10:1 by weight against this
relief structure, a negative of the relief was formed in the PDMS.
The microchannels measured 200 µm wide by 10-15 µm deep.
The device was through-bored at the ends of the channels to allow
fluids access to the channels when the PDMS device was applied
to a surface. Fluid flow was driven by applying vacuum to one
access point on the microchannel while connecting the other
access point to a reservoir of solution.
(12) Lee, Y. C.; Lee, R. T. Acc. Chem. Res. 1995, 28, 321-327.
(13) Lee, R. T.; Lee, Y. C. Glycoconjugate J. 2000, 17, 543-551.
(14) Horan, N.; Yan, L.; Isobe, H.; Whitesides, G. M.; Kahne, D. Proc. Natl. Acad.
Sci. U.S.A. 1999, 96, 11782-11786.
(15) Soltyk, A. M.; MacKenzie, C. R.; Wolski, V. M.; Hirama, T.; Kitov,
P. I.; Bundle, D. R.; Brunton, J. L. J. Biol. Chem. 2002, 277, 5351-
5359.
(16) Kitov, P. I.; Sadowska, J. M.; Mulvey, G.; Armstrong, G. D.; Ling, H.; Pannu,
N. S.; Read, R. J.; Bundle, D. R. Nature 2000, 403, 669-672.
(17) Kitova, E. N.; Kitov, P. I.; Bundle, D. R.; Klassen, J. S. Glycobiology 2001,
11, 605-611.
Arrays were fabricated by placing PDMS channel structures
in conformal contact with gold surfaces. Solutions consisting of
0.8-1 mM of the disulfides in 1:9 H2O/MeOH were injected into
(18) Mulvey, G. L.; Marcato, P.; Kitov, P. I.; Sadowska, J.; Bundle, D. R.;
Armstrong, G. D. J. Infect. Dis. 2003, 187, 640-649.
(19) Duverger, E.; Frison, N.; Roche, A.-C.; Monsigny, M. Biochimie 2003, 85,
167-179.
(20) Schengrund, C.-L. Biochem. Pharmacol. 2003, 65, 699-707.
(21) Kensinger, R. D.; Yowler, B. C.; Benesi, A. J.; Schengrund, C.-L. Bioconjugate
Chem. 2004, 15, 349-358.
(26) Pale-Grosdemange, C.; Simon, E. S.; Prime, K. L.; Whitesides, G. M. J. Am.
Chem. Soc. 1991, 113, 12-20.
(27) Aherne, D.; Rao, S. N.; Fitzmaurice, D. J. Phys. Chem. B 1999, 103, 1821-
1825.
(28) Kitov, P. I.; Railton, C.; Bundle, D. R. Carbohydr. Res. 1998, 307, 361-
369.
(22) Gustafson, I. Colloids Surf. B 2003, 30, 13-24.
(23) Critchley, P.; Clarkson, G. J. Org. Biomol. Chem. 2003, 1, 4148-4159.
(24) Kuziemko, G. M.; Stroh, M.; Stevens, R. C. Biochemistry 1996, 35, 6375-
6384.
(29) Kitov, P. I.; Paszkiewicz, E.; Wakarchuk, W. W.; Bundle, D. R. Methods
Enzymol. 2003, 362, 86-105.
(30) Mulvey, G.; Vanmaele, R.; Mrazek, M.; Cahill, M.; Armstrong, G. D. J.
Microbiol. Methods 1998, 32, 247-252.
(25) MacKenzie, C. R.; Hirama, T.; Lee, K. K.; Altman, E.; Young, N. M. J. Biol.
Chem. 1997, 272, 5533-5538.
(31) Xia, Y.; Whitesides, G. M. Angew. Chem., Int. Ed. Engl. 1998, 37, 550-
575.
7498 Analytical Chemistry, Vol. 77, No. 23, December 1, 2005